Even een quote van de Engelse wiki:
Methylbenzodioxolylbutanamine (MBDB; Methyl-J; "Eden") is a psychedelic, stimulant, and empathogen-entactogen of the phenethylamine chemical class. MBDB is a closely related chemical analogue of methylenedioxymethamphetamine (MDMA; "Ecstasy", "Adam", "Empathy", "E", "X", "XTC"), with the only difference between the two molecules being an ethyl group instead of a methyl group attached to the alpha carbon.
MBDB was first synthesized by David E. Nichols, a leading pharmacologist and medicinal chemist, and later tested by Alexander Shulgin and described in his book, PiHKAL (Phenethylamines i Have Known And Loved). MBDB's dosage, according to PiHKAL, is 180–210 mg; the proper dosage relative to body mass seems unknown. Its duration is 4–6 hours, with noticeable after-effects lasting for 1–3 hours.
MBDB was initially developed as a non-psychedelic entactogen. It has lower effects on the dopamine system in comparison to other entactogens such as MDMA. MBDB causes many mild, MDMA-like effects, such as lowering of social barriers and inhibitions, pronounced sense of empathy and compassion, mood lift, and mild euphoria are all present. MBDB tends to produce less euphoria, psychedelia, and stimulation in comparison. Many users declare that MBDB is a "watered-down" version of MDMA. Despite these features which make MBDB less desirable as a recreational drug, it has been suggested that the drug may have greater therapeutic potential than MDMA.
Unlike MDMA, MBDB is not internationally scheduled under the United Nations Convention on Psychotropic Substances. The thirty-second meeting of the WHO Expert Committee on Drug Dependence (September 2000) evaluated MBDB and recommended against scheduling. From the WHO Expert Committee assessment of MBDB:
Although MBDB is both structurally and pharmacologically similar to MDMA, the limited available data indicate that its stimulant and euphoriant effects are less pronounced than those of MDMA. There have been no reports of adverse or toxic effects of MBDB in humans. Law enforcement data on illicit trafficking of MBDB in Europe suggest that its availability and abuse may now be declining after reaching a peak during the latter half of the 1990s. For these reasons, the Committee did not consider the abuse liability of MBDB would constitute a significant risk to public health, thereby warranting its placement under international control. Scheduling of MBDB was therefore not recommended.